ImmunoCellular Therapeutics Ltd.
IMUC
PINL
Sector: Healthcare
Industry: Biotechnology
0.00
USD
0.00
(0.21%)
Optionable: No Market Cap: 0 M 90-day average vol: 1,873
Previous close: 0.234 Open: 0.234 Bid: Ask:
52 week range
0.14 0.75
Last updated: Tuesday 19th April 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Returns
Risk
Custom Beta One Year | 0.00 |
Custom Beta Three Years | 0.00 |
Beneish M Score | 0.00 |
Altman Z Score | -26.48 |
Dividends
Financial Health
Technicals
RSI (14 Day) | 54.01 |
14 Day SMA ($) | 0.23 |
14 Day EMA ($) | 0.23 |
Money Flow Index | 29.10 |
Average True Range | 0.09 |
50 Day SMA ($) | 0.00 |
200 Day SMA ($) | 0.00 |
ADX | 0.00 |
MACD | 0.00 |
Growth
Free Cash Flow QoQ Growth | 35.60% |
Free Cash Flow YoY Growth | -16.09% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -50.00% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | -84.41% |
Profitability
Chart
News
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement
Yahoo Finance 12/2/2021
ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market
Yahoo Finance 6/28/2021
Immunic (IMUC) Presents At Stifel Healthcare Conference - Slideshow
Seeking Alpha 11/20/2019
ImmunoCellular up 37% on asset sale
Seeking Alpha 7/17/2019
FDA finalizes guidance for expedited review of cell and gene therapy applications
Seeking Alpha 2/15/2019
ImmunoCellular Therapeutics to delist stock; shares down 73% after hours
Seeking Alpha 10/15/2018
ImmunoCellular Therapeutics reports Q2 results
Seeking Alpha 8/13/2018
ImmunoCellular Therapeutics announces settlement terms of federal class action shareholder lawsuit
Seeking Alpha 7/19/2018
ImmunoCellular Therapeutics reports Q1 results
Seeking Alpha 5/14/2018
ImmunoCellular advances Stem-to-T-Cell technology; shares up 27% premarket
Seeking Alpha 4/12/2018
ImmunoCellular Therapeutics receives audit opinion with going concern explanation
Seeking Alpha 3/26/2018
ImmunoCellular Therapeutics' (IMUC) CEO Anthony Gringeri on Q4 2017 Results - Earnings Call Transcript
Seeking Alpha 3/13/2018
ImmunoCellular Therapeutics reports FY results
Seeking Alpha 3/13/2018
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Financials
IMUC Income Statement
Annual
| Dec-08 | Dec-09 | Dec-10 | Dec-11 | Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 300000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of sales | -2075 | -3397 | -3633 | -20357 | -45823 | -50402 | -47656 | -36193 | -75114 | -47768 |
| Gross operating profit | 0 | 300000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling Gen & administrative expense | 2 M | 2 M | 3 M | 4 M | 4 M | 4 M | 4 M | 5 M | 5 M | 4 M |
| Research & development expense | 1 M | 962526 | 2 M | 5 M | 8 M | 5 M | 6 M | 11 M | 19 M | 17 M |
| Operating income | -3 M | -3 M | -5 M | -9 M | -12 M | -9 M | -10 M | -16 M | -24 M | -21 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 0 | 0 | -1 M | 3 M | -2 M | 642411 | 529774 | 3 M | 4 M | 8 M |
| Pre-tax Income (EBT) | -3 M | -3 M | -6 M | -6 M | -14 M | -9 M | -9 M | -13 M | -22 M | -14 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -3 M | -3 M | -6 M | -6 M | -14 M | -9 M | -9 M | -13 M | -22 M | -14 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -3 M | -3 M | -6 M | -6 M | -14 M | -9 M | -9 M | -13 M | -22 M | -14 M |
| Preferred dividends | 0 | 0 | 2 M | 0 | 0 | 0 | 0 | 0 | 0 | 2 M |
| Net income available for common | -3 M | -3 M | -8 M | -6 M | -14 M | -9 M | -9 M | -13 M | -22 M | -17 M |
| Depreciation | 2075 | 3397 | 3633 | 20357 | 45823 | 50402 | 47656 | 36193 | 75114 | 47768 |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -3 M | -3 M | -5 M | -6 M | -14 M | -9 M | -9 M | -13 M | -21 M | -13 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -9.6 | -7.6 | -17.2 | -8.4 | -14 | -6.4 | -6.4 | -6 | -7.89 | -1.23 |
| Diluted EPS total | -9.6 | -7.6 | -17.2 | -8.4 | -14 | -6.4 | -6.4 | -6 | -7.89 | -1.23 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!